Anti-CYP4A22 monoclonal antibody

Pre-made anti-CYP4A22 monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research

Target products collectionGo to CYP4A22/CYP4A22 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-IP0653-Ab-1/ GM-Tg-hg-IP0653-Ab-2Anti-Human CYP4A22 monoclonal antibodyHuman
GM-Tg-rg-IP0653-Ab-1/ GM-Tg-rg-IP0653-Ab-2Anti-Rat CYP4A22 monoclonal antibodyRat
GM-Tg-mg-IP0653-Ab-1/ GM-Tg-mg-IP0653-Ab-2Anti-Mouse CYP4A22 monoclonal antibodyMouse
GM-Tg-cynog-IP0653-Ab-1/ GM-Tg-cynog-IP0653-Ab-2Anti-Cynomolgus/ Rhesus macaque CYP4A22 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-IP0653-Ab-1/ GM-Tg-felg-IP0653-Ab-2Anti-Feline CYP4A22 monoclonal antibodyFeline
GM-Tg-cang-IP0653-Ab-1/ GM-Tg-cang-IP0653-Ab-2Anti-Canine CYP4A22 monoclonal antibodyCanine
GM-Tg-bovg-IP0653-Ab-1/ GM-Tg-bovg-IP0653-Ab-2Anti-Bovine CYP4A22 monoclonal antibodyBovine
GM-Tg-equg-IP0653-Ab-1/ GM-Tg-equg-IP0653-Ab-2Anti-Equine CYP4A22 monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-IP0653-Ab-1/ GM-Tg-hg-IP0653-Ab-2; GM-Tg-rg-IP0653-Ab-1/ GM-Tg-rg-IP0653-Ab-2;
GM-Tg-mg-IP0653-Ab-1/ GM-Tg-mg-IP0653-Ab-2; GM-Tg-cynog-IP0653-Ab-1/ GM-Tg-cynog-IP0653-Ab-2;
GM-Tg-felg-IP0653-Ab-1/ GM-Tg-felg-IP0653-Ab-2; GM-Tg-cang-IP0653-Ab-1/ GM-Tg-cang-IP0653-Ab-2;
GM-Tg-bovg-IP0653-Ab-1/ GM-Tg-bovg-IP0653-Ab-2; GM-Tg-equg-IP0653-Ab-1/ GM-Tg-equg-IP0653-Ab-2
Products NameAnti-CYP4A22 monoclonal antibody
Formatmab
Target NameCYP4A22
Protein Sub-locationIntrocelluar Protein
Category of antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected.
TagFc
Products descriptionPre-made anti-CYP4A22 monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-IP0653-Ag-1Recombinant multi-species CP4AM/ CYP4A22 protein


    Target information

    Target IDGM-IP0653
    Target NameCYP4A22
    Gene ID284541
    Gene Symbol and SynonymsCYP4A22
    Uniprot AccessionQ5TCH4
    Uniprot Entry NameCP4AM_HUMAN
    Protein Sub-locationIntrocelluar Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000162365
    Target ClassificationN/A

    The target: CYP4A22, gene name: CYP4A22, also named as . This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This gene is part of a cluster of cytochrome P450 genes on chromosome 1p33. Alternative splicing results in multiple transcript variants encoding different isoforms. [provided by RefSeq, Apr 2015].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.